» Articles » PMID: 33895315

Which Factors Matter the Most? Revisiting and Dissecting Antibody Therapeutic Doses

Overview
Specialty Pharmacology
Date 2021 Apr 25
PMID 33895315
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Factors such as antibody clearance and target affinity can influence antibodies' effective doses for specific indications. However, these factors vary considerably across antibody classes, precluding direct and quantitative comparisons. Here, we apply a dimensionless metric, the therapeutic exposure affinity ratio (TEAR), which normalizes the therapeutic doses by antibody bioavailability, systemic clearance and target-binding property to enable direct and quantitative comparisons of therapeutic doses. Using TEAR, we revisited and dissected the doses of up to 60 approved antibodies. We failed to detect a significant influence of target baselines, turnovers or anatomical locations on antibody therapeutic doses, challenging the traditional perceptions. We highlight the importance of antibodies' modes of action for therapeutic doses and dose selections; antibodies that work through neutralizing soluble targets show higher TEARs than those working through other mechanisms. Overall, our analysis provides insights into the factors that influence antibody doses, and the factors that are crucial for antibodies' pharmacological effects.

Citing Articles

Rat as a Predictive Model for Human Clearance and Bioavailability of Monoclonal Antibodies.

Robarge J, Budge K, Her L, Patterson A, Brown-Augsburger P Antibodies (Basel). 2025; 14(1.

PMID: 39846610 PMC: 11755617. DOI: 10.3390/antib14010002.


Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products.

Green P, Schneider A, Lange J MAbs. 2024; 16(1):2402713.

PMID: 39279181 PMC: 11407384. DOI: 10.1080/19420862.2024.2402713.


Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice.

Kulesza A, Couty C, Lemarre P, Thalhauser C, Cao Y J Pharmacokinet Pharmacodyn. 2024; 51(6):581-604.

PMID: 38904912 PMC: 11795844. DOI: 10.1007/s10928-024-09930-x.


Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms.

De Sutter P, Gasthuys E, Vermeulen A J Pharmacokinet Pharmacodyn. 2023; 51(6):639-651.

PMID: 37952005 DOI: 10.1007/s10928-023-09894-4.


Clearance as an Early Indicator of Efficacy for Therapeutic Monoclonal Antibodies: Circumventing Dose Selection Challenges in Oncology.

Chen C, Fan X, Zhang L, Xu P, Zou H, Zhao X Clin Pharmacokinet. 2023; 62(5):705-713.

PMID: 36930421 DOI: 10.1007/s40262-023-01231-9.


References
1.
Liang M, Schwickart M, Schneider A, Vainshtein I, Del Nagro C, Standifer N . Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development. Cytometry B Clin Cytom. 2015; 90(2):117-27. PMC: 5042057. DOI: 10.1002/cyto.b.21259. View

2.
Carter P, Lazar G . Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Nat Rev Drug Discov. 2017; 17(3):197-223. DOI: 10.1038/nrd.2017.227. View

3.
Bensch F, Lamberts L, Smeenk M, Jorritsma-Smit A, Lub-de Hooge M, van Scheltinga A . Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors. Clin Cancer Res. 2017; 23(20):6128-6137. PMC: 5642894. DOI: 10.1158/1078-0432.CCR-17-0311. View

4.
Agrawal S, Feng Y, Roy A, Kollia G, Lestini B . Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer. 2016; 4:72. PMC: 5109842. DOI: 10.1186/s40425-016-0177-2. View

5.
Freeman D, McDorman K, Ogbagabriel S, Kozlosky C, Yang B, Doshi S . Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Mol Cancer. 2012; 11:47. PMC: 3499177. DOI: 10.1186/1476-4598-11-47. View